First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up ...

Novo Nordisk said it had agreed to license a potential rival to its weight-loss drug Ozempic from a Chinese company. The ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

U.S. shares in Novo Nordisk, a leading maker of anti-obesity drugs, were down roughly 4% Wednesday afternoon. But shares in Eli Lilly, the other major weight-loss player, were little changed.

Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down just under 1%. The impact to Novo's stock is largely due to the CagriSema news earlier this week, along with the ...

Novo Nordisk A/S has a twelve month low of $73.80 and a twelve month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.